Fortitude 4.0
Fortitude 4.0
The MiRXES Fortitude 4.0 Kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs, nasopharyngeal wash/aspirate, nasal wash/aspirate and anterior/mid-turbinate nasal swabs samples from patients suspected of COVID-19 by a healthcare provider.

Key Features
Two-target
multiplex RT-PCR
Detection of the ORF1ab and N regions of the SARS-CoV-2 genome in one reaction.
Fast
results
1h 30min turnaround time after RNA extraction.
Reliable
performance
High sensitivity and specificity. Zero cross-reactivity with 31 different respiratory tract-associated organisms.
Lab
ready
Compatible with current industry-standard RT-PCR instruments and data analysis software without any additional installations.
Quality
assured
End-to-end process validated.
Details
MiRXES Fortitude 4.0 is a real-time RT-PCR intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs, nasopharyngeal wash/aspirate, nasal wash/aspirate and anterior/mid-turbinate nasal swabs samples from patients suspected of COVID-19 by a healthcare provider.
The RNA from SARS-CoV-2 is generally detectable in upper respiratory during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.
Regulatory Status
MiRXES Fortitude 4.0 has received CE Mark and is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures.
Detection Target | Channel | |
---|---|---|
1 | SARS-CoV-2 ORF 1ab gene | FAM |
2 | SARS-CoV-2 N gene | HEX/VIC |
3 | Human RNase P gene | Cy5 |
Specifications | Values |
---|---|
Limit of Detection | 0.25 GE/µL |
Inclusivity | >99.8% have 100% homology to either N or ORF1ab target as of 16th February 2021 including B.1.1.7 lineage and B.1.351 lineage. |
Cross reactivity | No cross-reactivity with 31 respiratory tract-associated organisms |
Clinical sensitivity | 96.8% (CI: 89.0% – 99.1%) |
Clinical specificity | 96.2% (CI: 87.0% – 98.9%) |
Ordering Information
Product | Pack Size | Contents | Catalogue No. |
---|---|---|---|
Fortitude 4.0 | 200 reactions/kit | Primers-Probes Mix, Reverse Transcriptase, Universal Probes Reaction Mix, Positive Control, Negative Control | FGS0006R (RUO), FGS0006 |
The test is only provided for use by clinical laboratories or Research Use Only (RUO).
Contact Us
Singapore (Global HQ)
Tel: +65 6816 2931
Email: sales@mirxes.com
Available Downloads:
- IFU for Fortitude 4.0
- MSDS for Fortitude 4.0

SOCIAL MEDIA
- Genomics
- Clinical Sequencing
- Research Sequencing
- Cancer Screening
- GASTROClear for Patients
- GASTROClear for Medical Professionals
- LUNGClear
- Cancer Treatment Selection
- APEX Tissue Panel for Medical Professionals
- Infectious Diseases
- Fortitude 2.1
- Fortitude 3.0
- Fortitude Syndromic Panel
- CoVClear Mutation Panel
- Swab & Saliva Collection
- RNA Extraction Kit & Instruments